We are live on ! Find out more
STLN

Starling Oncology Institute, Inc. Common Stock

Positive
Neutral
Negative
Sentiment 3-Months
Positive 31.3%
Neutral 68.8%
Negative 0%

Neutral
GlobeNewsWire
3 days ago
The Oncology Institute Rebrands as Starling Oncology
CERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.
The Oncology Institute Rebrands as Starling Oncology
Neutral
GlobeNewsWire
9 days ago
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
CERRITOS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its second quarter 2026 financial results on Thursday, August 6, 2026, to be followed by a conference call the same day at 5:00 p.m.
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call
Positive
Zacks Investment Research
29 days ago
Best Cheap Stocks Under $10 to Buy Now in July
One area of Wall Street that investors might want to start buying are strong, best-in-class, cheap stocks trading under $10 a share in July and throughout the rest of 2026.
Best Cheap Stocks Under $10 to Buy Now in July
Neutral
GlobeNewsWire
29 days ago
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
CERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed.
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity
Positive
InvestorPlace
1 month ago
2 More Stocks to Buy for the AI Convergence
Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.
2 More Stocks to Buy for the AI Convergence
Positive
Zacks Investment Research
1 month ago
The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?
The Oncology Institute (TOI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock?
Neutral
InvestorPlace
1 month ago
3 Stocks to Buy for the AI Convergence
Tom Yeung here with your Sunday Digest . In 2025, two professors wanted to see whether ChatGPT made people less creative.
3 Stocks to Buy for the AI Convergence
Positive
Zacks Investment Research
1 month ago
How Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%
The average of price targets set by Wall Street analysts indicates a potential upside of 38.1% in The Oncology Institute (TOI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in The Oncology Institute (TOI)? Wall Street Analysts Think 38.07%
Positive
Benzinga
1 month ago
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Neutral
GlobeNewsWire
2 months ago
Topicus.com Inc. Announces a Revised Proposal to Acquire ReadyTech
TORONTO, May 31, 2026 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV: TOI), acting through its subsidiary TSS Europe B.V. (“TSS”), today submitted a revised non-binding indicative proposal to acquire ReadyTech Holdings Limited (ASX: RDY) (“ReadyTech”) by way of a scheme of arrangement for cash consideration of $2.00 per share (the “Scheme Consideration”), or in the alternative, an off-market takeover bid with a 50.1% minimum acceptance condition at a cash consideration of $1.75 per share (the "Takeover Consideration") (together, the "Revised Proposal")1. All references herein to currency are in Australian dollars.
Topicus.com Inc. Announces a Revised Proposal to Acquire ReadyTech